biosystem

Jesse Jacobs’ pantone panoply Safari Honeymoon has been reviewed by A.V. Club.

“When reading Jesse Jacobs’ Safari Honeymoon the primary feeling is one of total immersion. It’s not just a graphic novel about a newlywed couple taking their honeymoon in a strange, dangerous environment, it’s a sensory experience that engulfs the reader in an intricately detailed biosystem of horrific parasites, alien foliage, and geometric spirits.” — Oliver Sava, A.V. Club

Read the whole review here!

T2 Biosystems Receives FDA Authorization to Market T2Candida and T2Dx for ...

T2 Biosystems Receives FDA Authorization to Market T2Candida and T2Dx for …

T2 Biosystems Receives FDA Authorization to Market T2Candida and T2Dx for
Both T2Candida and T2Dx were reviewed under the FDA de novo classification process for devices with low-to-moderate risk that are first-of-a-kind. Studies have shown that if Candida can be diagnosed and treated with targeted therapy … Due to the high …
Read more on GlobeNewswire (press release)

New ICD-10 Coding System…

View On WordPress

I’m always doing this, but I was looking at schools that offer my major or along the lines of it. And my major now is biosystems/agricultural engineering, which I want to stay for undergrad because the department is just so lovely (I’m not in it yet , you don’t get to be in it freshmen year but I’ve been in it and met professors). Anywho, Northeastern has a really good bioengineering graduate program and I’ve been in the dumps lately because of people, ect, but this made me so happy because it’s in Boston and they work a lot in sustainability in Boston and all I want to do is be closer to family and work in alternative energy. I can’t wait for the next years to come!

The GEN 'Top 17 Serial Bio Entrepreneurs' List Includes Colorado's Michael Bristow and Marvin Caruthers

Quoting from the December 15th GEN posting:

"The average number of businesses launched by serial entrepreneurs has most often been quoted at 2.3, the figure furnished by the Kauffman Foundation for Entrepreneurship in ‘The Anatomy of an Entrepreneur,’ a 2009 study of 549 founders in industries that included biotechnology…Yet judging from this year’s updated GEN List of serial entrepreneurs, and the original List published in 2012, biotech entrepreneurs are among the most enterprising entrepreneurs."

Here are Colorado’s contributors to our nation’s the “serial bio entrepreneurs” fold:

Michael R. Bristow, M.D., Ph.D
Founded Myogen
Co-Founded miRagen and ARCA biopharma
Currently: Professor of Medicine in Cardiology and Co-Director of the University of Colorado Cardiovascular Institute at UC Denver School of Medicine

Marvin H. Caruthers, Ph.D.
Co-Founded miRagen Therapeutics, Array BioPharma, Applied Biosystems and Amgen
Served as Founding Investor for Dharmacon
Currently: Distinguished Professor of Chemistry and Biochemistry at the University of Colorado

Link to GEN

In attesa della seconda stagione ecco una carrellata di materiale promozionale per la serie Helix, targata Syfy.

Dopo il primo ciclo di episodi, le nuove puntate vedranno sempre come protagonista Billy Campbell (The Killing) con il ruolo del dottor Alan Farragut e il suo team del Centro per le malattie infettive. Le vicende, che nella prima avevano coinvolto la crisi Narvik avvenuta all’Arctic Biosystems, saranno dedicati a un’indagine relativa allo scoppio di un’epidemia scoppiata a bordo di un veliero. Gli indizi condurranno a un’isola abitata da un culto che vuole creare una società utopica.

Il leader della setta, chiamato Brother Michael, sarà un esperto genetista di fama mondiale, interpretato da Steven Weber (Chasing Life).

Ecco la galleria di immagini promozionale del cast:

Così dopo aver ottenuto ottimi ascolti con la prima stagione, Helix si appresta a ritornare sempre sul network Syfy il 16 gennaio. Qui di seguito trovate anche una serie di teaser rilasciati dallo stesso canale:

http://cms.springboardplatform.com/embed_iframe/677/video/1269335/sotv036/Spoilertv.com/10/1/

http://cms.springboardplatform.com/embed_iframe/677/video/1269337/sotv036/Spoilertv.com/10/1/

http://cms.springboardplatform.com/embed_iframe/677/video/1269339/sotv036/Spoilertv.com/10/1/

Helix 2/immagini promozionali e alcuni teaser In attesa della seconda stagione ecco una carrellata di materiale promozionale per la serie Helix, targata…

Researchers led by Martin Fussenegger, biotechnology and biomechanics professor of the Department of Biosystems at Federal Institute of Technology (ETH) in Zurich, developed a gene network that uses brain waves to control gene expression, or the conversion of genes into proteins. The technology has been successfully tested in human cells grown in the laboratory and in lab mice. The results were published in the journal «Nature Communications».

The device was operated with the help of an electronic headset, worn on the head and functioning as electroencephalogram recorder. The recorded brain waves were then analyzed and transmitted via Bluetooth to an electronic implant that generated an electromagnetic field and was placed inside the body. The implant was also equipped with a tiny LED lamp, which emitted light in the near-infrared portion of the electromagnetic spectrum. This type of light was used because it is not harmful to human cells but at the same time can penetrate deep into tissues, which allows visual monitoring of the implant.

In accordance with one’s thoughts, brain waves caused the light of the implant to switch on or switch off, which, in turn, activated or deactivated certain genes in cells, leading them to produce more or less of a particular protein, in this case the SEAP. The experiments were conducted with the participation of volunteers and showed that the more focused they were in trying to switch on genes in mice with their thoughts, the greater the amount of the produced protein was.

VALENCIA, SPAIN (Marketwired Dec 17, 2014) - Zenosense, Inc. (OTCQB: ZENO) ( Zenosense , the Company ), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA Super-Bug and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company s development partner, Zenon Biosystem (Zenon) entered into a collaboration agreement for a lung cancer detection trial. The agreement is with a university and a large university hospital located in the region of Madrid, Spain. The trial will facilitate clinical tests on breath samples from 400 people, in line with the previously announced protocol design.  The Company is delighted that the university research scientists and the university hospital have all recognised the potential for our technology. A positive outcome may be a significant step toward a major healthcare breakthrough: Currently less than 20% of lung cancer is detected in the relatively t

Swiss Scientists Control Genes with the Power of Mind

by Anna LeMindLearning MindResearchers from Switzerland have developed an innovative gene regulation device operated via brain waves.Researchers led by Martin Fussenegger, biotechnology and biomechanics professor of the Department of Biosystems at Federal Institute of Technology (ETH) in Zurich, developed a gene network that uses brain waves to control gene expression, or the conversion of genes into proteins. The technology has been successfully tested in human cells grown in the laboratory and in lab mice. The results were published in the journal - Nature Communications». The device was operated with the help of an electronic headset, worn on the head and functioning as electroencephalogram recorder. http://b4in.com/aI21

#Biotech CH3 BioSystems – methyl marks discovery: CH3 BioSystems is a biotech company manufacturing novel mole... http://t.co/W3ZAJxVrHu

#Biotech CH3 BioSystems – methyl marks discovery: CH3 BioSystems is a biotech company manufacturing novel mole… http://t.co/W3ZAJxVrHu

#Biotech CH3 BioSystems – methyl marks discovery: CH3 BioSystems is a biotech company manufacturing novel mole… http://t.co/W3ZAJxVrHu

— Biotech 365 (@Biotech365) December 11, 2014

View On WordPress


Zenosense, Inc. (OTCQB: ZENO), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce that on 16 December 2014, the Company’s development partner, Zenon Biosystem (Zenon) entered into a collaboration agreement for a lung cancer detection trial.